Satellos Bioscience's Share Rise After Sat-3247 Shows Positive Results for Duchenne MD

Dow Jones

Jul 08

Shares of Satellos Bioscience rose after it reported its investigational drug candidate SAT-3247 for adults living with Duchenne muscular dystrophy showed positive results.

The stock was up 16% to $9.49 in recent trading, and rose 61% since the start of the year.

The data from its Trailhead evaluation showed reduced fat friction, increased effort in upper limbs and increased handgrip strength. Satellos, a biotechnology company, primarily develops novel therapies to treat degenerative muscle diseases.

Perry Shieh, a professor at UCLA's David Geffen School of Medicine, said the consistency across measures of strength, muscle composition and safety in the data was highly encouraging for the evaluation of SAT-3247.

Chief Executive Frank Gleeson said the results were encouraging for Basecamp, another phase 2 study for SAT-3247, which is on track to complete enrollment by the end of the third quarter.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 08, 2026 10:56 ET (14:56 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2649992366"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2649992366\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2649992366?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649992366","market":"sg","top_or_hot":-1,"title":"Satellos Bioscience's Share Rise After Sat-3247 Shows Positive Results for Duchenne MD","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Satellos Bioscience rose after it reported its investigational drug candidate SAT-3247 for adults living with Duchenne muscular dystrophy showed positive results. \n</p>\n<p>\n  The stock was up 16% to $9.49 in recent trading, and rose 61% since the start of the year. \n</p>\n<p>\n  The data from its Trailhead evaluation showed reduced fat friction, increased effort in upper limbs and increased handgrip strength. Satellos, a biotechnology company, primarily develops novel therapies to treat degenerative muscle diseases. \n</p>\n<p>\n  Perry Shieh, a professor at UCLA's David Geffen School of Medicine, said the consistency across measures of strength, muscle composition and safety in the data was highly encouraging for the evaluation of SAT-3247. \n</p>\n<p>\n  Chief Executive Frank Gleeson said the results were encouraging for Basecamp, another phase 2 study for SAT-3247, which is on track to complete enrollment by the end of the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 10:56 ET (14:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Satellos Bioscience's Share Rise After Sat-3247 Shows Positive Results for Duchenne MD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSatellos Bioscience's Share Rise After Sat-3247 Shows Positive Results for Duchenne MD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-08 22:56</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Satellos Bioscience rose after it reported its investigational drug candidate SAT-3247 for adults living with Duchenne muscular dystrophy showed positive results. \n</p>\n<p>\n  The stock was up 16% to $9.49 in recent trading, and rose 61% since the start of the year. \n</p>\n<p>\n  The data from its Trailhead evaluation showed reduced fat friction, increased effort in upper limbs and increased handgrip strength. Satellos, a biotechnology company, primarily develops novel therapies to treat degenerative muscle diseases. \n</p>\n<p>\n  Perry Shieh, a professor at UCLA's David Geffen School of Medicine, said the consistency across measures of strength, muscle composition and safety in the data was highly encouraging for the evaluation of SAT-3247. \n</p>\n<p>\n  Chief Executive Frank Gleeson said the results were encouraging for Basecamp, another phase 2 study for SAT-3247, which is on track to complete enrollment by the end of the third quarter. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 10:56 ET (14:56 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MD","symbol_name":"Pediatrix Medical","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649992366","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649992366","pubTimestamp":1783522560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Satellos Bioscience rose after it reported its investigational drug candidate SAT-3247 for adults living with Duchenne muscular dystrophy showed positive results.The stock was up 16% to $9.49 in recent trading, and rose 61% since the start of the year.The data from its Trailhead evaluation showed reduced fat friction, increased effort in upper limbs and increased handgrip strength. Satellos, a biotechnology company, primarily develops novel therapies to treat degenerative muscle diseases.Perry Shieh, a professor at UCLA's David Geffen School of Medicine, said the consistency across measures of strength, muscle composition and safety in the data was highly encouraging for the evaluation of SAT-3247.Chief Executive Frank Gleeson said the results were encouraging for Basecamp, another phase 2 study for SAT-3247, which is on track to complete enrollment by the end of the third quarter.Write to Grace Yoon at grace.yoon@wsj.com Dow Jones NewswiresJuly 08, 2026 10:56 ET Copyright  2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MD":"Pediatrix Medical","BK4196":"保健护理服务"},"translate_title":"Sat-3247为Duchenne MD带来积极成果后，Satellos Bioscience的股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MD":1.5},"content_text":"Shares of Satellos Bioscience rose after it reported its investigational drug candidate SAT-3247 for adults living with Duchenne muscular dystrophy showed positive results. \n\n\n  The stock was up 16% to $9.49 in recent trading, and rose 61% since the start of the year. \n\n\n  The data from its Trailhead evaluation showed reduced fat friction, increased effort in upper limbs and increased handgrip strength. Satellos, a biotechnology company, primarily develops novel therapies to treat degenerative muscle diseases. \n\n\n  Perry Shieh, a professor at UCLA's David Geffen School of Medicine, said the consistency across measures of strength, muscle composition and safety in the data was highly encouraging for the evaluation of SAT-3247. \n\n\n  Chief Executive Frank Gleeson said the results were encouraging for Basecamp, another phase 2 study for SAT-3247, which is on track to complete enrollment by the end of the third quarter. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 10:56 ET (14:56 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}